Phase I, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study of Intravenous APL-9 in Healthy Volunteers
Latest Information Update: 28 Jul 2020
At a glance
- Drugs APL 9 (Primary)
- Indications Stroke
- Focus Adverse reactions
- 18 Jul 2019 Results published in the Apellis Pharmaceuticals Media Release.
- 09 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 30 May 2018 Planned number of patients changed from 24 to 30.